Novo Nordisk Faces Investor Backlash and Legal Woes Amid Stock Decline

Novo Nordisk (NVO) shareholders are confronting mounting challenges as the pharmaceutical giant's stock slides. A 10% drop last week and a 34% year-to-date decline have left investors uneasy. The sentiment downturn coincides with a U.S. class-action lawsuit window opening for those who held shares between May and July 2024.

Legal troubles compound the pressure. Ozempic, Novo's blockbuster semaglutide drug for type 2 diabetes, faces potential litigation over alleged inadequate warning labels. Emerging studies LINK higher doses to gastroparesis—a severe digestive condition—prompting several U.S. law firms to prepare compensation claims.

The dual pressures of eroding shareholder value and expanding legal risks create a pivotal moment for Novo Nordisk. Market observers note the irony of investors potentially joining lawsuits against the company responsible for their previous gains.